Barclays Maintains an 'Underweight' on Omnicare (OCR); 'New and Improved' Senior Management Meetings Review
Tweet Send to a Friend
Barclays maintains an 'Underweight' on Omnicare (NYSE: OCR), PT $32.
Barclays analyst says, "The biggest takeaway is that Omnicare's new ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "The biggest takeaway is that Omnicare's new ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
